Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components

Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961

Rift Valley fever: biology and epidemiology

Wright D. et al, (2019), Journal of General Virology, 100, 1187 - 1199

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197

Association between Rift Valley fever virus seroprevalences in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County, Kenya

Bett B. et al, (2019), Epidemiology and Infection, 147

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Allen ER. et al, (2018), Cell Reports, 25, 3750 - 3758.e4

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

Rampling T. et al, (2018), npj Vaccines, 3

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection

O’Shea MK. et al, (2018), Scientific Reports, 8

Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials

Bowyer G. et al, (2018), Vaccines, 6, 50 - 50

CHARACTERIZING THE IMMUNE RESPONSE TO RIFT VALLEY FEVER VIRUS IN MULTIPLE SPECIES AFTER NATURAL EXPOSURE OR VACCINATION WITH CHADOX1-RVF

Wright D. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 424 - 424

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model

Munster VJ. et al, (2017), npj Vaccines, 2

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™

Venkatraman N. et al, (2017), Vaccine, 35, 6208 - 6217

IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN

Wright D. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 95, 412 - 412

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

Mensah VA. et al, (2016), PLOS ONE, 11, e0167951 - e0167951

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

Ewer K. et al, (2016), New England Journal of Medicine, 374, 1635 - 1646

Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle

Dulal P. et al, (2016), Vaccine, 34, 2296 - 2298

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever

Warimwe GM. et al, (2016), Scientific Reports, 6

Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN® FILO in healthy UK adults

Rampling T. et al, (2015), Journal of Infection, 71, 688 - 688

BOOSTING THE NOVEL EBOLA VACCINE CANDIDATE CHADEBOV Z WITH MODIFIED VACCINIA VIRUS ANKARA (MVA) SIGNIFICANTLY ENHANCES EBOLA-SPECIFIC ANTIBODY RESPONSES

Bowyer G. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 54 - 54

IMPACT ON IMMUNOGENICITY OF VARYING THE INTERVAL BETWEEN THE PRIME AND BOOST OF A CANDIDATE EBOLA VACCINE CHAD3-EBO Z AND MVA-BN FILO IN HEALTHY UK ADULTS

Wright D. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 54 - 55

SAFETY AND IMMUNOGENICITY OF THE HETEROLOGOUS PRIME-BOOST EBOLAVIRUS VACCINE REGIMEN CHAD3-EBO Z AND MVA-BN® FILO IN HEALTHY UK ADULTS

Rampling T. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 446 - 447

SAFETY, IMMUNOGENICITY AND EFFICACY OF THE COMBINATION MALARIA VACCINE REGIMEN OF RTS, S/AS01B CONCOMITANTLY ADMINISTERED WITH CHAD-MVA VIRAL VECTORS EXPRESSING ME-TRAP

Rampling T. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 391 - 391

Include forthcoming?